Bangladesh's Beximco signs Covid-19 vaccine deal with India's Serum Institute1 min read . Updated: 29 Aug 2020, 05:58 AM IST
The deal announced by the Bangladeshi generic drugmaker comes after Dhaka said this month it was ready to hold trials of candidate vaccines being developed by India as both countries seek to curb the spread of the virus
DHAKA: Bangladesh's Beximco Pharmaceuticals is investing in the Serum Institute of India (SII) to ensure Dhaka gets priority access to COVID-19 vaccines being developed by the Indian drug manufacturer, the company said on Friday.
Select your Category